波音游戏-波音娱乐城赌球打不开

Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs
20210518_1.jpeg

Published on Angewandte Chemie (18 May 2021)

 

Author(s): Zoufeng Xu, Zhigang Wang, Zhiqin Deng, Guangyu Zhu*

 

Abstract

Platinum-based anticancer drugs have been widely applied in clinical settings for more than 40 years. The remarkable breakthroughs that have come from the use of these complexes in cancer therapy have stimulated a continual search for new platinum anticancer drugs. The most promising result of these efforts is a prodrug strategy based on the use of platinum(IV) versions of the traditional platinum(II) anticancer drugs. Hence, the design of synthetic methods for platinum(IV) prodrugs and an understanding of their hydrolytic stability and intracellular activation processes are critical for the development of platinum(IV) prodrugs for cancer therapy. In this review, we summarize recent progress in this field from a comprehensive viewpoint, with an emphasis first on the oxidation processes in chemical environments where platinum(II) compounds are converted to their platinum(IV) species, followed by the reduction processes in biological environments where platinum(IV) species are converted back to platinum(II) forms. First, recent approaches that use new oxidizing reagents to synthesize platinum(IV) prodrugs are summarized, and the oxidation mechanisms and outer-sphere functionalization of platinum(IV) prodrugs are examined. Second, the hydrolysis of platinum(IV) complexes, which has sometimes been underexplored, is discussed, and the factors associated with the hydrolytic stability of platinum(IV) complexes are reviewed. Last, we focus on the reduction of platinum(IV) prodrugs, from the perspectives of reduction potential, rate of reduction, reducing agents, and reduction products. The need for new strategies to achieve controllable intracellular reduction of platinum(IV) prodrugs is emphasized. This review aims to help researchers to improve their understanding of platinum(IV) anticancer prodrugs and hopefully to generate new ideas, strategies, and applications in the area of metal-based drugs.

 

20210518_2.jpeg


Read more: https://doi.org/10.1016/j.ccr.2021.213991

 

 

background
 
 
 
 
 
 
 
 
大连百家乐官网商场| 百家乐博乐城| 大哥大百家乐官网的玩法技巧和规则| 屏山县| 赤壁百家乐娱乐城| 百家乐10个人| 永利高百家乐信誉| 赌博百家乐官网经验| 乐九百家乐官网现金网| 上高县| 百家乐官网视频打麻将| 豪博百家乐官网现金网| 百家乐官网棋牌公式| 太仓市| 百家乐官网最新投注法| 真人百家乐官网好不好玩| 万豪娱乐网| 金宝博188| 皇冠足球比分网| 青神县| 青神县| 玩百家乐官网技巧看路| 百家乐官网技巧在那里| 百家乐官网破解策略| 百家乐官网汝河路| 百家乐赌场软件| 威尼斯人娱乐中心老品牌| 大发888网页多少| 大发888娱乐城m88| 宝马会娱乐城网址| 百家乐官网最佳投注法下载| 百家乐官网论坛代理合作| 澳门百家乐论谈| 伯爵百家乐娱乐平台| 大发888卡| 六合彩报码聊天室| 网上百家乐官网骗人不| 狮威百家乐官网娱乐城| 博彩通| 新澳门百家乐官网软件下载| 百家乐官网玩法规|